AVEO Pharmaceuticals Inc

AVEO Pharmaceuticals — Investor Presentation (November 2019)

36 slides from AVEO Pharmaceuticals's investor presentation, Nov 5, 2019

  1. Slide 1: AVEO Overview November 2019

    AVEO Overview November 2019

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements

  3. Slide 3: AVEO Oncology: Strategy for Value Creation

    | AVEO Oncology: Strategy for Value Creation Deep Pipeline Addressing Significant Unmet Needs Multiple oncology and non-oncology pipeline opportunities FOTIVDA® (tivozanib) — 10 Combinations (RCC, HCC, other) Selective VEGFR TKI has potential to enable unique tolerability in combination ONCOLOGY [cu

  4. Slide 4: Multiple Potential Opportunities for Value Creation

    Multiple Potential Opportunities for Value Creation

  5. Slide 5: Financial Highlights

    Financial Highlights Cash on hand to fund planned operations into 3Q 2021* * $40.2M in cash, cash equivalents, and marketable securities as of 2Q 2019 + $25.0M upfront payment from Kyowa Kirin received in 3Q 2019 * Runway includes paydown of debt, randomized phase 2 studies for ficlatuzumab in SCCHN

  6. Slide 6: FOTIVDA (tivozanib) TIVO-3 Pivotal Phase Study

    FOTIVDA® (tivozanib) TIVO-3 Pivotal Phase 3 Study

  7. Slide 7: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor

    Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor

  8. Slide 8: TIVO-3: Study Design

    TIVO-3: Study Design First stratified 3rd line dataset of patients with prior PD-1 exposure TIVO3 Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma N=350 Fd * Recurrent/metastatic RCC Ss | tivoz

  9. Slide 9: TIVO-3: Superior PFS and ORR

    TIVO-3: Superior PFS and ORR*

  10. Slide 10: Progression-Free Survival – Key Subgroups

    Progression-Free Survival – Key Subgroups*

  11. Slide 11: Durable Disease Control with Tivozanib (Patients with > year PFS)

    Durable Disease Control with Tivozanib (Patients with > 1 year PFS)

  12. Slide 12: Secondary Endpoint – Overall Survival

    Secondary Endpoint – Overall Survival

  13. Slide 13: Pre-NDA Regulatory Feedback and POA

    Pre-NDA Regulatory Feedback and POA

  14. Slide 14: As OS Data Matures HR Improves

    As OS Data Matures HR Improves

  15. Slide 15: Treatment-Related Adverse Events (≥20% frequency in either arm)

    Treatment-Related Adverse Events* (≥20% frequency in either arm)

  16. Slide 16: Safety and Tolerability Results TIVO3

    Safety and Tolerability Results* TIVO3 Tivozanib (N=173)* | Sorafenib (N=170)* Mean Number of Cycles Initiated 11.9 6.7 AEs Leading to Dose Reductions (%) 24 P=0.005 38 AEs Leading to Dose Interruption (%) 48 P=0.007 63 Treatment Related SAEs (%) 12 11 Treatment Related Deaths (%) fo) 0 Deaths withi

  17. Slide 17: TIVO-3 Conclusions

    TIVO-3 Conclusions TIVO-3 * Tivozanib significantly improves PFS and ORR compared to sorafenib in patients with treatment-refractory advanced RCC Y Tivozanib was superior in patients previously treated with checkpoint inhibitors as well as two VEGFR-TKIs v Responses with tivozanib were more durable

  18. Slide 18: PD-1 Combination Opportunities

    PD-1 Combination Opportunities

  19. Slide 19: Tivozanib Properties May Provide Advantages in Combination with IO Therapy

    Tivozanib Properties May Provide Advantages in Combination with IO Therapy

  20. Slide 20: Phase Data Presented at ESMO in September 2019

    Phase 2 Data Presented at ESMO in September 2019

  21. Slide 21: ESMO 2019: Encouraging Safety Results

    ESMO 2019: Encouraging Safety Results

  22. Slide 22: ESMO 2019: Encouraging Efficacy

    ESMO 2019: Encouraging Efficacy

  23. Slide 23: Combination of PD-1 + VEGF TKIs: Promising Responses, All Phase 3 Currently 1st Line

    Combination of PD-1 + VEGF TKIs: Promising Responses, All Phase 3 Currently 1st Line

  24. Slide 24: TiNivo – Strong Efficacy Seen in Both Treatment Naive and Previously Treated Patients

    TiNivo – Strong Efficacy Seen in Both Treatment Naive and Previously Treated Patients

  25. Slide 25: Immuno-Oncology Clinical Collaboration with AstraZeneca

    Immuno-Oncology Clinical Collaboration with AstraZeneca

  26. Slide 26: Tivozanib Commercial Opportunity

    Tivozanib Commercial Opportunity

  27. Slide 27: If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States

    If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States

  28. Slide 28: Potential Relevance of Tivozanib in Refractory RCC

    Potential Relevance of Tivozanib in Refractory RCC

  29. Slide 29: FOTIVDA Commercialization in EU and ROW

    FOTIVDA® Commercialization in EU and ROW

  30. Slide 30: Pipeline and Near-Term Milestones

    Pipeline and Near-Term Milestones

  31. Slide 31: Tivozanib

    Tivozanib VEGER 1, 2 and 3 Tyrosine Kinase Inhibitor Launched in Europe by EUSA as FOTIVDA? in first line RCC in November 2017 TIVO-3 study on-going for potential U.S. registration for RCC Tivozanib + OPDIVO® Phase 1/2 in collaboration with BMS complete in RCC Tivozanib + IMFINZI® Phase 1/2 in colla

  32. Slide 32: Ficlatuzumab

    2 Ficlatuzumab biodesix ® HGF Inhibitory Antibody with Optimal Blockade of c-Met * AML: Phase 1/2 trial of ficlatuzumab and cytarabine in refractory AML patients (n=18) * Demonstrated 50% CR in patients refractory to initial therapy * Randomized Phase 2 in planning * SCCHN: Randomized Phase 2 trial

  33. Slide 33: AV-203 (CAN017)

    AVv-203 (CANO17) OCANbridge Anti-ERBB3 MAb with Broad Therapeutic Potential CANbridge to fund clinical development through Phase 2 POC study Potential additional $40.0M development and regulatory/$90.0M commercial milestone Tiered low double-digit royalties for ex-NA rights Planned indication: squam

  34. Slide 34: AV-380: First-in-Class, Anti-GDF15 MAb for Cachexia

    AV-380 First-in-Class, Anti-GDF15 MAb for Cachexia * Cachexia affects approximately 5 million patients in the U.S. alone; affects up to 80% of advanced cancer patients and is responsible for approximately 30% of all cancer deaths! * Pre-clinical development underway to enable planned IND submission

  35. Slide 35: AVEO Key Near Term Potential Milestones

    AVEO Key Near Term Potential Milestones

  36. Slide 36: AVEO Overview November 2019

    AVEO Overview November 2019

AVEO Pharmaceuticals — Investor Presentation (November 2019) on 6ix